PolyActiva has showcased their Phase 2 clinical data for their lead candidate PA5108 Ocular Implant in glaucoma patients.
Patients received continuous therapy for intraocular pressure (IOP) for over 48 weeks, receiving their first and second implants at week 0 and 21 respectively. Clinically meaningful IOP reductions of 26-35% were observed over the 48-week treatment period, and 94% of patients did not require additional drop therapy.